Nascent Biotech, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutic agents targeting oncology and inflammatory diseases. The company’s core expertise lies in leveraging antibody engineering, cell therapy platforms, and small molecule inhibitors to advance a diversified pipeline of drug candidates. Research and development efforts are conducted at its state‐of‐the‐art laboratories in San Diego, California, with complementary collaborations and licensing agreements across North America and Europe.
Since its founding in 2005, Nascent Biotech has pursued an integrated approach that spans target identification, preclinical validation, and early‐stage clinical trials. Lead programs include an engineered monoclonal antibody for solid tumors, a CAR T‐cell therapy platform designed to enhance tumor specificity, and a proprietary oral agent aimed at modulating key inflammatory pathways. Preclinical data have demonstrated promising safety and efficacy profiles, supporting the initiation of Phase I studies in select oncology indications.
Nascent Biotech maintains strategic partnerships with academic institutions and contract research organizations to accelerate translational research and manufacturing scalability. The company’s global footprint extends to collaborative research sites in the United Kingdom and Japan, enabling access to diverse patient populations and regulatory expertise. Nascent’s leadership team combines seasoned biotech executives and scientific pioneers, ensuring robust governance and a clear roadmap for clinical advancement.
Under the direction of President and CEO Dr. Jane Smith, an industry veteran with over two decades of drug development experience, Nascent Biotech continues to strengthen its intellectual property portfolio and expand its pipeline through in‐licensing and co‐development opportunities. The organization remains committed to advancing innovative therapies that address unmet medical needs and deliver tangible clinical benefits to patients worldwide.
AI Generated. May Contain Errors.
Free NBIO Stock Alerts